Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12904173 | 0.87 | AURKA (0.43) | AURKAJAK1TYK2KDRFLT3 | |
| SCHEMBL12904171 | 0.82 | AURKA (0.46) | AURKAJAK1TYK2KDRFLT3 | |
| SCHEMBL1160321 | 0.80 | BRD4 (0.30) | BRD4CREBBP | |
| SCHEMBL2359234 | 0.78 | DGAT1 (0.35) | DGAT1BRD4CREBBP | |
| SCHEMBL1159822 | 0.77 | — | — | |
| SCHEMBL1159987 | 0.77 | — | — | |
| SCHEMBL1159824 | 0.77 | — | — | |
| SCHEMBL1933692 | 0.76 | AURKA (0.36) | AURKAJAK1KDRFLT3DGAT1 | |
| SCHEMBL12904146 | 0.73 | — | — | |
| SCHEMBL21632466 | 0.73 | FEN1 (0.36) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8361962-B2 | Tricyclic inhibitors of JAK | ROCHE PALO ALTO LLC (US) | 2013-01-29 | — | — | US | disclosed |
| US-8361962-B2 | Tricyclic inhibitors of JAK | ROCHE PALO ALTO LLC (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2459566-A1 | TRICYCLIC INHIBITORS OF JAK | F. Hoffmann-La Roche AG (CH) | 2012-06-06 | — | — | EP | disclosed |
| WO-2011012540-A1 | TRICYCLIC INHIBITORS OF JAK | F. HOFFMANN-LA ROCHE AG (CH) | 2011-02-03 | — | — | WO | disclosed |
| US-20110021425-A1 | TRICYCLIC INHIBITORS OF JAK | BILLEDEAU ROLAND JOSEPH | 2011-01-27 | — | — | US | disclosed |
| US-20110021425-A1 | TRICYCLIC INHIBITORS OF JAK | BILLEDEAU ROLAND JOSEPH | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021425-A1 | TRICYCLIC INHIBITORS OF JAK | JAK3, JAK1, JAK2 | AURKA 1442/4885JAK1 2/4885TYK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.